Community-acquired pneumonia
Conditions
Interventions
Antibiotic Domain a.Ceftriaxone and Macrolide b.Levofloxacin c.Piperacillin-tazobactam and Macrolide
Macrolide Duration Domain: a.Macrolide administered for 3-5 days b.Macrolide administered for
Sponsors
St. Marianna University School of Medicine Department of Emergency and Critical Care Medicine,
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [In case of community acquired pneumonia] 1 Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with: a. symptoms or signs or both that are consistent with lower respiratory tract infection AND b. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate) 2)Up to 48 hours after ICU admission, receiving organ support with one or more of: a.Non-invasive or Invasive ventilatory support; b.Receiving infusion of vasopressor or inotropes or both [In case of COVID-19] Adult patients hospitalized to an acute healthcare facility due to confirmed COVID-19 infection
Exclusion criteria
Exclusion criteria: [In case of community acquired pneumonia] 1. Healthcare-associated pneumonia: a.Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days b.Resident of a nursing home or long term care facility 2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 3. Previous participation in this REMAP within the last 90 days [In case of COVID-19] 1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 2. The patient is expected to be discharged on the day or on the following day 3. The patient has been hospitalized due to the acute illness caused by the pandemic infection for more than 14 days. 4. Previous participation in this REMAP within the last 90 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality (Time Frame: Day 90) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 ICU Mortality (Time Frame: Day 90) 2 ICU length of stay (Time Frame: Day 90) 3 Hospital length of stay (Time Frame: Day 90 ) 4 Ventilator free days (Time Frame: Day 28) 5 Organ failure free days (Time Frame: Day 28) 6 All-cause mortality (Time Frame: 6 months) 7 Health-related Quality of life assessment (Time Frame: 6 months) EQ5D-5L and WHODAS 2.0 (not completed in all regions) 8 Proportion of intubated patients who receive a tracheostomy (Time Frame: Day 28) 9 Destination at time of hospital discharge (Time Frame: Free text Day 90) Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital 10 Readmission to the index ICU during the index hospitalization (Time Frame: Day 90 ) 11 World Health Organisation 8-point ordinal scale outcome (Time Frame: Hospital discharge) 12 Days alive and not receiving organ support in ICU (Time Frame: Day 21) | — |
Countries
Japan
Contacts
Public ContactShigeki Fujitani
St. Marianna University School of Medicine Department of Emergency and Critical Care Medicine
Outcome results
None listed